Fundz

Fundz Deep Dive

Everything you need to win Chris H. Takimoto — in one platform.

Who to reach, what to say, and why now on Chris H. Takimoto — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Chris H. Takimoto — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

the Start Center for Cancer Research Appoints Chris H. Takimoto As Chief Medical Officer

PRIVATEOct 02, 2024•over 1 year ago

Position

Chief Medical Officer

Company

The START Center for Cancer Research

Chris H. Takimoto
San AntonioBiotechnologyHealth Care

Description

The START Center for Cancer Research proudly announces the appointment of Chris H Takimoto, MD, PhD, FACP, as its new Chief Medical Officer. Dr Takimoto, a renowned physician-scientist, oncology drug developer, and entrepreneur, brings a wealth of leadership experience and a distinguished career in both clinical and executive roles. In his new role at START, Dr Takimoto will lead scientific and medical strategies to position START as the global leader in community-based early phase cancer trials.

Company Information

Company

The START Center for Cancer Research

Location

San Antonio, Texas, United States

About

The START Center for Cancer Research is deeply rooted in community oncology centers globally, providing access to specialized preclinical and Phase 1 clinical trials of novel anti-cancer agents. It represents the world’s largest roster of Principal Investigators (PIs) across its global network and has conducted over 1,300 Phase 1 clinical trials, contributing to the development of 43 FDA/EMA-approved therapies.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for The START Center for Cancer Research's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.